Vaccines
Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals
Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty
FDA’s Peter Marks Advocates for Open Dialogue on Vaccines Amid Controversy
FDA, Peter Marks, Vaccines, Open Dialogue, RFK Jr, HHS Nomination
Vaccine Stocks Plummet Globally Following RFK Jr.’s Nomination to Head HHS
RFK Jr., HHS appointment, vaccine stocks, pharmaceutical companies, stock market impact
RFK Jr.’s HHS Nomination: A Potential Threat to the Biopharma Industry
RFK Jr., HHS nomination, biopharma industry, vaccine skepticism, health policies, Trump administration
Moderna’s COVID-19 Vaccine Sales Exceed Expectations, but RSV Vaccine Falls Short
Moderna, COVID-19 vaccine, RSV vaccine, vaccine sales, pharmaceutical industry
Coherus Resumes Biosimilar Supply Following Temporary Disruption; Novavax Terminates COVID-19 Vaccine Deal with UK
Coherus BioSciences, Biosimilar supply, UDENYCA, Supply chain issues, Novavax, COVID-19 vaccine deal, UK
Medidata Introduces Bundled Solutions for Oncology and Vaccine Trials to Enhance Study Efficiency
Medidata, Oncology Trials, Vaccine Trials, Bundled Solutions, Clinical Trial Efficiency, Patient-Centered Endpoints, Adaptive Trial Designs, Trial Diversity
BioNTech Beats Q3 Expectations but Trims Full-Year Revenue Guidance Amid COVID-19 Vaccine Sales
BioNTech, Q3 earnings, COVID-19 vaccine, Revenue guidance, Oncology development, mRNA-based immunotherapies
Merck’s Gardasil Sales in China Continue to Decline Amid Economic and Regulatory Challenges
Merck, Gardasil, China, vaccine sales, economic challenges, regulatory issues
GSK’s Vaccine Sales Plummet in Q3, Highlighting Reduced Demand and Market Challenges
GSK, vaccine sales, third quarter, reduced demand, Arexvy, Shingrix, influenza vaccine